172 related articles for article (PubMed ID: 24768122)
1. Current and investigational drug strategies for glioblastoma.
Ajaz M; Jefferies S; Brazil L; Watts C; Chalmers A
Clin Oncol (R Coll Radiol); 2014 Jul; 26(7):419-30. PubMed ID: 24768122
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
3. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
4. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
[TBL] [Abstract][Full Text] [Related]
5. Current chemotherapy for glioblastoma.
Parney IF; Chang SM
Cancer J; 2003; 9(3):149-56. PubMed ID: 12952300
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Groves MD; Maor MH; Meyers C; Kyritsis AP; Jaeckle KA; Yung WK; Sawaya RE; Hess K; Bruner JM; Peterson P; Levin VA
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):127-35. PubMed ID: 10477016
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
[TBL] [Abstract][Full Text] [Related]
9. How did lomustine become standard of care in recurrent glioblastoma?
Weller M; Le Rhun E
Cancer Treat Rev; 2020 Jul; 87():102029. PubMed ID: 32408220
[TBL] [Abstract][Full Text] [Related]
10. PCV chemotherapy for recurrent glioblastoma multiforme.
Boiardi A
Neurology; 2001 Jun; 56(12):1782. PubMed ID: 11425963
[No Abstract] [Full Text] [Related]
11. Comparative efficacy of bevacizumab and PCV chemotherapy in recurrent glioblastoma.
Dixit S; Hingorani M
Clin Oncol (R Coll Radiol); 2015 Apr; 27(4):246-7. PubMed ID: 25659888
[No Abstract] [Full Text] [Related]
12. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Levin VA; Maor MH; Thall PF; Yung WK; Bruner J; Sawaya R; Kyritsis AP; Leeds N; Woo S; Rodriguez L
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):357-64. PubMed ID: 7673023
[TBL] [Abstract][Full Text] [Related]
13. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Martikainen JA; Kivioja A; Hallinen T; Vihinen P
Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
[TBL] [Abstract][Full Text] [Related]
16. Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Carvalho BF; Fernandes AC; Almeida DS; Sampaio LV; Costa A; Caeiro C; Osório L; Castro L; Linhares P; Damasceno M; Vaz RC
Oncol Res Treat; 2015; 38(7-8):348-54. PubMed ID: 26278578
[TBL] [Abstract][Full Text] [Related]
17. Repurposing drugs for glioblastoma: From bench to bedside.
Basso J; Miranda A; Sousa J; Pais A; Vitorino C
Cancer Lett; 2018 Aug; 428():173-183. PubMed ID: 29729291
[TBL] [Abstract][Full Text] [Related]
18. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
[TBL] [Abstract][Full Text] [Related]
19. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.
Kuhnhenn J; Kowalski T; Steenken S; Ostermann K; Schlegel U
J Neurooncol; 2012 Sep; 109(2):433-8. PubMed ID: 22744756
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]